Compare ATLO & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLO | CRBU |
|---|---|---|
| Founded | 1903 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.2M | 203.9M |
| IPO Year | N/A | 2021 |
| Metric | ATLO | CRBU |
|---|---|---|
| Price | $27.38 | $1.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 36.7K | ★ 1.2M |
| Earning Date | 01-23-2026 | 03-09-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ 88.22 | N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $65,795,000.00 | $9,295,000.00 |
| Revenue This Year | N/A | $0.22 |
| Revenue Next Year | N/A | $4.48 |
| P/E Ratio | $12.80 | ★ N/A |
| Revenue Growth | ★ 23.09 | N/A |
| 52 Week Low | $16.09 | $0.66 |
| 52 Week High | $28.35 | $3.54 |
| Indicator | ATLO | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 74.19 | 45.46 |
| Support Level | $27.06 | $1.45 |
| Resistance Level | $28.35 | $1.65 |
| Average True Range (ATR) | 0.74 | 0.11 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 75.49 | 33.33 |
Ames National Corporation is a United States-based bank holding company. It provides short-term and medium-term commercial, multi-family, and agricultural real estate loans, residential real estate loans, agricultural and business operating loans and lines of credit, equipment loans, vehicle loans, personal loans and lines of credit, home improvement loans and origination of mortgage loans for sale into the secondary market. The Banks also offer a variety of checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit and automated/video teller machine access. The banking segment generates revenues through personal, business, agricultural and commercial lending, and Others.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.